EYEN Eyenovia Inc.

5.16
+0.04  (+1%)
Previous Close 5.12
Open 5.09
Price To Book 4.96
Market Cap 62018804
Shares 12,019,148
Volume 11,195
Short Ratio
Av. Daily Volume 60,005

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated mid-2019.
MicroPine
Myopia
Phase 3 trial not required - plan to proceed with registration activities in 2019.
MicroTears
Dry eye disease
NDA filing due 2020.
MicroStat
Mydriasis - pupil dilation
Phase 3 trial to be initiated late-2019.
MicroProst
Chronic angle closure glaucoma (CACG)

Latest News

  1. Eyenovia Reports First Quarter 2019 Financial Results
  2. Introducing Eyenovia (NASDAQ:EYEN), The Stock That Dropped 33% In The Last Year
  3. Eyenovia Announces Conference Call and Webcast for First Quarter 2019 Financial Results
  4. Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results
  5. Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results
  6. Eyenovia to Participate in Two Upcoming Investor Conferences
  7. Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis
  8. Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering
  9. Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
  10. Biotech Stocks to Watch
  11. Biotechs Investors Are Flocking To
  12. 4 Healthcare Stocks Raising The Bar On Wednesday (1/30/19)
  13. Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis
  14. Do Institutions Own Eyenovia, Inc. (NASDAQ:EYEN) Shares?
  15. 4 Healthcare Stocks to Watch on Wednesday (12/19/18)
  16. Eyenovia Prices Public Offering of Common Stock
  17. Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
  18. Eyenovia Announces Publication of its PG21 Phase II Trial Results Demonstrating Robust IOP Lowering Effect and Patient Usability